SCN9A Gene Generalized Epilepsy with Febrile Seizures Plus Type 7 (GEFS+7) Genetic Test in UAE | 2800 AED

Executive Summary & Core Metrics

Comprehensive Genetic Assessment

This next-generation sequencing (NGS) test analyzes the complete coding region of the SCN9A sodium voltage-gated channel gene to provide a definitive molecular diagnosis for autosomal dominant Generalized Epilepsy with Febrile Seizures Plus Type 7 (GEFS+7). Priced at 2,800 AED, the test delivers results within 3 to 4 weeks from sample receipt. Genetic counseling and a detailed clinical report are included, enabling targeted treatment planning and familial risk assessment.

Test Overview & Methodology

The SCN9A GEFS+7 assay employs next-generation sequencing (NGS) technology to interrogate all exons and flanking intronic regions of the SCN9A gene. Bioinformatics analysis includes copy-number variant (CNV) detection, ensuring comprehensive coverage of pathogenic single-nucleotide variants, small insertions or deletions, and structural rearrangements. The test achieves an analytical sensitivity and specificity exceeding 99.9% for clinically relevant variants, supporting accurate diagnosis and informed clinical decision-making.

Feature	Our Test (NGS Full Gene Sequencing with CNV Analysis)	Closest Alternative (Targeted Genotyping / Whole Exome Sequencing)
Precision	>99.9% analytical sensitivity and specificity for SCN9A variants	Limited to known SNPs; may miss rare or novel mutations
Method	NGS with copy-number variant detection	PCR-based genotyping or whole exome sequencing (longer turnaround, higher cost)
Turnaround Time	3 to 4 weeks	4 to 10 weeks
Regulatory Compliance	DHA-licensed, ISO-certified, UAE PDPL compliant	Variable; may lack local DHA accreditation

Physician Insight & Safety Protocols

“A thorough molecular evaluation of the SCN9A gene is essential for confirming GEFS+7 and guiding personalized antiseizure therapy. The NGS approach captures the full mutational spectrum, yet clinical correlation with electroclinical features and family history remains mandatory for accurate prognosis and genetic counseling.”

— Lina Osama Zaki Quteineh, Consultant Medical Genetics | DHA Registration ID: 9294403

Medication Advisory

Do not alter or stop any prescribed antiepileptic regimen without direct consultation with your treating neurologist. Abrupt changes in medication may precipitate breakthrough seizures or serious adverse events.

Safety & Exclusion Criteria

Individuals with uncorrected coagulopathy or severe needle phobia may provide an alternative sample (buccal swab or DNA FTA card).
Minors under 18 require legal guardian consent and a valid Emirates ID, in accordance with UAE regulatory standards.
Testing is not appropriate for persons who cannot comprehend the informed consent process.

Emergency Red Flags: If a seizure persists longer than 5 minutes, breathing difficulty arises, or signs of anaphylaxis occur after sample collection, call 998 immediately.

Patient FAQ & Clinical Guidance

1. What is the SCN9A GEFS+7 Genetic Test?

This test sequences the entire SCN9A gene to identify pathogenic variants linked to Generalized Epilepsy with Febrile Seizures Plus Type 7, an autosomal dominant familial epilepsy syndrome. The analysis includes both single-nucleotide changes and larger structural rearrangements.

2. How much does the test cost and is insurance accepted?

The test is priced at 2,800 AED. Direct billing verification is available for major UAE insurers via WhatsApp at +971 54 548 8731. Please contact our billing team prior to sample collection to confirm your coverage.

3. How should I interpret a positive or uncertain result?

A positive result identifies a disease-causing SCN9A variant, but clinical expression varies widely. Always review your results with a neurologist and a genetic counselor to understand the implications for treatment and family members. A variant of uncertain significance (VUS) may require further segregation analysis.

4. How is the sample collected and what is the turnaround time?

A peripheral whole blood sample is collected via standard venipuncture. Our VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection service is available daily from 8 AM to 11 PM. Results are delivered within 3 to 4 weeks from sample receipt.

UAE Regulatory & Data Privacy Adherence

All genetic data generated by this test is processed and stored in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety and patient consent protocols are governed by Federal Decree-Law No. 4 of 2016 on Medical Liability. DNA Labs UAE holds DHA Facility License No. 1143 and is committed to the highest standards of data confidentiality and ethical genetic testing.

Clinical & Logistical Metadata

Test Name	SCN9A Gene Generalized Epilepsy with Febrile Seizures Plus Type 7 (GEFS+7) Genetic Test
Price (AED)	2,800 AED
Turnaround Time	3 to 4 weeks
Sample Type / Matrix	Peripheral Whole Blood (VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily 8 AM – 11 PM)
Methodology Used	Next-Generation Sequencing (NGS) with Copy-Number Variant (CNV) Analysis
ICD-10-CM Code	G40.3, G40.8
LOINC Code	81326-5
DHA Facility License & Laboratory Address	DNA Labs UAE \| DHA License No. 1143 \| Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE